1,694 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Purchased by Brighton Jones LLC

Brighton Jones LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,694 shares of the medical research company’s stock, valued at approximately $234,000.

A number of other hedge funds have also modified their holdings of DGX. JPMorgan Chase & Co. grew its holdings in shares of Quest Diagnostics by 36.8% during the third quarter. JPMorgan Chase & Co. now owns 2,001,347 shares of the medical research company’s stock worth $243,884,000 after buying an additional 538,377 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Quest Diagnostics by 12.3% during the third quarter. American Century Companies Inc. now owns 3,554,517 shares of the medical research company’s stock worth $433,153,000 after buying an additional 388,162 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Quest Diagnostics by 14.6% during the third quarter. Wellington Management Group LLP now owns 2,613,793 shares of the medical research company’s stock worth $318,517,000 after buying an additional 333,947 shares in the last quarter. Pathstone Family Office LLC grew its holdings in shares of Quest Diagnostics by 2,400.9% during the third quarter. Pathstone Family Office LLC now owns 336,521 shares of the medical research company’s stock worth $41,008,000 after buying an additional 323,065 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc bought a new position in shares of Quest Diagnostics during the fourth quarter worth about $30,869,000. 88.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DGX has been the subject of a number of analyst reports. TheStreet downgraded Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. Leerink Partnrs restated a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. StockNews.com downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Friday. SVB Leerink initiated coverage on Quest Diagnostics in a research note on Monday, February 26th. They issued a “market perform” rating and a $135.00 price target for the company. Finally, Citigroup raised their price target on Quest Diagnostics from $135.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Ten investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $146.17.

Quest Diagnostics Stock Performance

DGX opened at $137.38 on Friday. The stock has a market cap of $15.26 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 2.96 and a beta of 0.88. The business has a 50 day moving average of $130.33 and a 200-day moving average of $131.71. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59. Quest Diagnostics Incorporated has a 12-month low of $119.59 and a 12-month high of $145.58.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.18. The business had revenue of $2.37 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period last year, the firm posted $2.04 EPS. On average, equities research analysts expect that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current year.

Insider Buying and Selling

In other Quest Diagnostics news, Director Vicky B. Gregg sold 2,500 shares of Quest Diagnostics stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the transaction, the director now directly owns 16,329 shares of the company’s stock, valued at approximately $2,067,904.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Quest Diagnostics news, Director Vicky B. Gregg sold 2,500 shares of Quest Diagnostics stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the transaction, the director now directly owns 16,329 shares of the company’s stock, valued at approximately $2,067,904.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Catherine T. Doherty sold 821 shares of Quest Diagnostics stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $103,560.94. Following the completion of the transaction, the executive vice president now directly owns 70,800 shares of the company’s stock, valued at $8,930,712. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,910 shares of company stock valued at $2,159,602. Insiders own 0.79% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.